Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K/mTOR/CDK4/6 inhibitors may influence the development of edema, which may cause or exacerbate progression of BCRL in patients with MBC.
|
30919166 |
2019 |
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these findings suggest that while <i>FGFR1</i> amplification confers broad resistance to ER, PI3K, and CDK4/6 inhibitors, mTOR inhibitors might have a unique therapeutic role in the treatment of patients with ER<sup>+</sup>/FGFR1<sup>+</sup> MBC.
|
31371343 |
2019 |
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.
|
29153866 |
2018 |
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.
|
29103666 |
2017 |
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggest that additional PI3K blockade might be effective in enhancing the therapeutic effect of tamoxifen in ER-positive BC and support the rationale combination in clinical trials.
|
28852212 |
2017 |
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Metastatic breast cancer (MBC) progressing after endocrine therapy frequently activates PI3K/AKT/mTOR pathway.
|
28727815 |
2017 |
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
|
27573562 |
2016 |
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
MYC gene copies, centromere status and PI3K activation may adversely impact trastuzumab treated mBC patient outcome and seem worthy validating in larger series.
|
27184134 |
2016 |
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
|
26497877 |
2015 |
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, resistance to a class I PI3K inhibitor in a model of metastatic breast cancer driven by PI3K and MYC was associated with feedback activation of tyrosine kinase receptors (RTKs), AKT, mTOR, and MYC.
|
26058079 |
2015 |
Carcinoma breast stage IV
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amplified PI3K/Akt/mTOR signaling is common in metastatic breast cancer (MBC).
|
26456573 |
2015 |
Carcinoma breast stage IV
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to determine the clinical activity of the PI3K inhibitor buparlisib (BKM120) in patients with HER2(+) advanced/metastatic breast cancer resistant to trastuzumab-based therapy.
|
24470511 |
2014 |
Carcinoma breast stage IV
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
|
24595002 |
2014 |
Carcinoma breast stage IV
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.
|
21490305 |
2011 |
Carcinoma breast stage IV
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we used low-density arrays, quantitative PCR, and western blotting to determine how HER2 signaling inhibition with lapatinib or PI3K inhibitors affects the expression of genes involved in breast cancer metastatic spread and overall prognosis.
|
20126311 |
2010 |